Keywords: عامل Hypomethylating; AML; HMA; Hypomethylating agent; Myelosysplastic syndrome;
مقالات ISI عامل Hypomethylating (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: عامل Hypomethylating; Acute myeloid leukemia; Myelodysplastic syndrome; Hypomethylating agent; Histone deacetylase inhibitor;
Keywords: عامل Hypomethylating; Effectiveness; Hematological malignancy; Hypomethylating agent; Overall survival; Stem cell transplantation;
Keywords: عامل Hypomethylating; MDS; Response; Stable disease; Hypomethylating agent
Keywords: عامل Hypomethylating; Myelodysplastic syndrome; Angiogenesis; Biomarker; Hypomethylating agent;
Keywords: عامل Hypomethylating; AMC; absolute monocyte count; AML; acute myeloid leukemia; BM; bone marrow; CMML; chronic myelomonocytic leukemia; CPSS; CMML-Specific Prognostic Scoring System; ESA; erythropoiesis-stimulating agent; GFM; Groupe Français des Myélodysplasies; GVHD; graf
Keywords: عامل Hypomethylating; CMML; Hypomethylating agent; Azacitidine; Splenomegaly; Survival;
SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
Keywords: عامل Hypomethylating; Del(5q); Hypomethylating agent; Lenalidomide; MDS; Treatment algorithm;
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia
Keywords: عامل Hypomethylating; ANC; Absolute neutrophil count; AML; Acute myeloid leukemia; BL; Baseline; BM; Bone marrow; CI; Confidence intervals; CMML; Chronic myelomonocytic leukemia; CR; Complete remission; ECOG; Eastern Cooperative Oncology Group; HI; Hematologic improvement; HI-
Epigenetics in myelodysplastic syndromes
Keywords: عامل Hypomethylating; MDS; Epigenetics; ASXL1; DNMT3A; EP300; EZH2; IDH1; IDH2; KDM2B; KDM5A; KDM6A; MLL; MLL2; MLL3; MLL5; TET2; WT1; Hypomethylating agent; HDAC inhibitor;
Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer
Keywords: عامل Hypomethylating; ALDH1; DNMT3b; Radiation; OSCC; Immune; Hypomethylating agent;
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization
Keywords: عامل Hypomethylating; ASXL1; Chronic myelomonocytic leukemia; Hypomethylating agent; Next-generation sequencing; TET2;
Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome
Keywords: عامل Hypomethylating; 5-Azacitidine; MDS; Hypomethylating agent; Allogeneic hematopoietic cell transplantation
Emerging Therapies in Hematopoietic Stem Cell Transplantation
Keywords: عامل Hypomethylating; Allogeneic; Proteasome; Bortezomib; HDAC; Hypomethylating agent; Azacytidine; Review
Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Keywords: عامل Hypomethylating; azacitidine; decitabine; hypomethylating agent; myelodysplastic syndrome (MDS)
Are we nearer to curing patients with MDS?
Keywords: عامل Hypomethylating; myelodysplastic syndromes, MDS; epidemiology; International Prognostic Scoring System, IPSS; erythropoiesis-stimulating agents, ESAs; lenalidomide; hypomethylating agent; DNA methyltransferase inhibitor; decitabine; azacitidine; clofarabine;
Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)â RNAs hybridized to 3â²-end flanking sequences of βmajor globin gene
Keywords: عامل Hypomethylating; MEL; Cell; Differentiation; Hypomethylating agent; Inducer; Globin gene; Transcription; Neplanocin A; 3-Deazaneplanocin A; Cycloleucine; Silent DNA; DNA methylation; RNA methylation;